SEATTLE, April 19, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has pleasure in announcing the appointment of George Cardona as a Strategic Advisor to the Board on corporate strategy and financial matters.
Mr. Cardona has extensive experience in banking and government. He was formerly a Special Advisor to the UK Treasury Department, followed by a career in banking with HSBC, where he was Head of Group Strategy and subsequently represented HSBC on the boards of numerous other banks and financial services companies around the world. After leaving HSBC he set up Cardona Lloyd & Co, an asset management and corporate finance advisory company which was later sold. He is currently a director of three natural resource companies: K+S, SUEK and EuroChem; and of several private investment holding companies.
Dr Glynn Wilson, Chairman & CEO of TapImmune, stated, "We welcome the appointment of George Cardona as a Strategic Advisor to the Board. George's extensive experience in global finance and corporate strategy will be of significant value in helping us build TapImmune into a fully capitalized global biotechnology organization. This appointment is consistent with the evolution of our world-class management and advisory team."
About TapImmune Inc.
TapImmune Inc. is a vaccine technologies company specializing in the development of innovative gene based immunotherapeutics and vaccines in the areas of oncology and infectious disease. The Company's lead product candidates, include vaccines designed to restore and augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The Company is currently preparing for the commencement of a Phase 1 immunotherapy clinical trial targeting Her2Neu in breast cancer using a patented technology developed at the Mayo clinic. TapImmune has the exclusive Option to license this technology. The Company is also developing TAP-based prophylactic vaccines commercially suitable for the prevention of infectious diseases and as Biodefense agents. As a vaccine component, the gene based TAP technology has the potential to significantly improve the efficacy of both prophylactic and immunotherapeutic vaccines as it addresses a fundamental mechanism for T cell recognition and response. Unlike other vaccine technologies that address only the initiation of immune responses, TAP expression also has the unique ability to enhance the effector function of mature killer T cells. This enhancement of effector function is potentially complementary to any/all vaccine approaches that are designed to enhance cellular responses.
The TapImmune Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3877
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.